Tag:
pancreatic cancer
Latest Headlines
Latest Headlines
Boston Scientific launches stent study for pancreatic cancer surgery
Boston Scientific enrolled its first patient in a study of its self-expanding WallFlex Biliary RX Stent to broaden the indication of the device for the purposes of draining bile before pancreatic cancer surgery.
New therapeutic target found for pancreatic cancer
Researchers at New York University's School of Medicine have discovered how pancreatic tumor cells feed themselves to grow and survive, uncovering new possible therapeutic target to treat the notoriously deadly type of cancer.
U.K. crew pursues DNA for early pancreatic cancer Dx
Researchers in the U.K. are taking up the task of developing a diagnostic that can detect pancreatic cancer much earlier than doctors are able to at the moment.
Bacteria deliver radioactive drugs to treat pancreatic cancer
To combat pancreatic cancer, notable for its staunch resistance to many treatments, researchers at the Albert Einstein College of Medicine in New York's Yeshiva University have turned to living bacteria that can deliver radioactivity directly to tumor cells.
Radioactive bacteria treatment stops metastasis in mice
A therapy derived from a weakened version of a deadly kind of bacteria reduced metastasis of pancreatic cancer in mice with no obvious ill effects, according to a new study.
Dx approach offers chance to spot pancreatic cancer earlier
With a five-year survival rate of less than 5%, pancreatic cancer is aggressive, deadly and an all-but-certain death sentence, in part because it is usually metastasized before doctors spot it. Japanese scientists have come up with a blood test that would screen for certain metabolites to help detect the disease earlier than current diagnostics allow, and potentially boost those survival odds.
FDA scrutinizing Merck's Januvia, BMS' Byetta
The FDA is taking a closer look at the increased risk of Type 2 diabetics getting pancreatic cancer from the popular drugs like Merck's blockbuster Januvia and Byetta from Bristol-Myers Squibb.
Celgene's Abraxane shows promise in pancreatic cancer
A drug that Celgene ($CELG) acquired in its $2.9 billion acquisition of Abraxis BioScience in 2010 is showing promise against the notoriously hard-to-treat p ancreatic cancer.
Celgene keeps biotech spotlight with sanguine Abraxane data in pancreatic cancer
Celgene CEO Bob Hugin is leading a push to rapidly grow the major drugmaker, keeping the company atop lists of go-to partners among biotechs.
New target could improve treatment of deadly pancreatic cancer
With the 5-year survival rate for pancreatic cancer at just 6%--the lowest among all major killer cancers--finding a treatment for the disease could literally be lifesaving for patients.
